All In Biotech

Drug Trial Radar · NCT07549841

Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Nantes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transthyretin cardiac amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by amyloid fibril deposition, leading to heart failure and arrhythmias. Despite advances in diagnosis, the disease remains commonly unrecognized and presents heterogeneously. Recent therapies targeting transthyretin stabilization and gene silencing have improved outcomes, but current staging systems based on biological and functional markers have limited ability to guide treatment. Imaging techniques such as cardiac magnetic resonance (CMR) provide tissue characterization, but noninvasive molecular imaging of myocardial fibrotic activity remains limited. Positron emission tomography (PET) tracers targeting fibroblast activation protein (FAPI), labeled with gallium-68 (68Ga), offer a promising approach to detect and quantify fibroblast activity associated with myocardial remodeling. This study aims to evaluate \[68Ga\]Ga-FAPI PET imaging for staging ATTR-CM and distinguishing patients with disease progression under therapy. The investigators hypothesize that \[68Ga\]Ga-FAPI uptake reflects fibrotic activity correlating with disease severity and progression. If validated, \[68Ga\]Ga-FAPI PET could serve as a novel biomarker for improved staging and personalized strategies in ATTR-CM.

Conditions

  • Transthyretin Cardiac Amyloidosis

Interventions

  • [68Ga]Ga-FAPI-46Drug

    \[68Ga\]Ga-FAPI-46 PET acquisition at approximatively 40 min after the injection over 20-45 minutes. The PET imaging will be associated with either MRI or CT at the investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of quantitative evaluation of [68Ga]Ga-FAPI-46 cardiac uptakeTime frame: within 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chu Nantes

    Nantes, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.